Canada Markets closed

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.9000-0.0400 (-2.06%)
At close: 4:00PM EDT
1.9500 +0.05 (+2.63%)
After hours: 07:04PM EDT

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797
http://www.aimimmuno.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas K. Equels Esq., J.D., M.S.Exec. Vice Chairman, CEO & Pres1.52MN/A1953
Ms. Ellen M. LintalCFO & Chief Accounting Officer441.99kN/A1959
Mr. Peter W. Rodino III, Esq., J.D.COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.681.86kN/A1951
Dr. David R. StrayerChief Scientific Officer & Medical DirectorN/AN/A1946
Ann Marie E. CoverlyDirector of Admin. & HR and Deputy Investor Relations CoordinatorN/AN/AN/A
Dr. Carol A. SmithChief Manufacturing Officer & Deputy Chief Scientific OfficerN/AN/A1951
Julie MierauControllerN/AN/AN/A
Dr. Ralph Christopher CavalliVP of QC & ManufacturingN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.

Corporate Governance

AIM ImmunoTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.